QQQ   258.82 (-0.80%)
AAPL   385.03 (-1.50%)
MSFT   204.02 (-1.93%)
FB   240.37 (+0.04%)
GOOGL   1,506.39 (-0.69%)
AMZN   3,007.87 (-0.03%)
NVDA   405.55 (-0.87%)
CGC   18.42 (+1.49%)
BABA   244.00 (-2.09%)
MU   50.00 (-1.01%)
GE   7.10 (-0.56%)
TSLA   1,507.14 (-2.51%)
AMD   54.53 (-1.48%)
T   30.22 (+0.70%)
ACB   12.28 (-4.58%)
F   6.86 (+1.78%)
GILD   76.28 (-0.48%)
DIS   119.74 (-0.98%)
NFLX   528.65 (+1.03%)
BAC   23.91 (-2.84%)
BA   180.60 (-3.91%)
QQQ   258.82 (-0.80%)
AAPL   385.03 (-1.50%)
MSFT   204.02 (-1.93%)
FB   240.37 (+0.04%)
GOOGL   1,506.39 (-0.69%)
AMZN   3,007.87 (-0.03%)
NVDA   405.55 (-0.87%)
CGC   18.42 (+1.49%)
BABA   244.00 (-2.09%)
MU   50.00 (-1.01%)
GE   7.10 (-0.56%)
TSLA   1,507.14 (-2.51%)
AMD   54.53 (-1.48%)
T   30.22 (+0.70%)
ACB   12.28 (-4.58%)
F   6.86 (+1.78%)
GILD   76.28 (-0.48%)
DIS   119.74 (-0.98%)
NFLX   528.65 (+1.03%)
BAC   23.91 (-2.84%)
BA   180.60 (-3.91%)
QQQ   258.82 (-0.80%)
AAPL   385.03 (-1.50%)
MSFT   204.02 (-1.93%)
FB   240.37 (+0.04%)
GOOGL   1,506.39 (-0.69%)
AMZN   3,007.87 (-0.03%)
NVDA   405.55 (-0.87%)
CGC   18.42 (+1.49%)
BABA   244.00 (-2.09%)
MU   50.00 (-1.01%)
GE   7.10 (-0.56%)
TSLA   1,507.14 (-2.51%)
AMD   54.53 (-1.48%)
T   30.22 (+0.70%)
ACB   12.28 (-4.58%)
F   6.86 (+1.78%)
GILD   76.28 (-0.48%)
DIS   119.74 (-0.98%)
NFLX   528.65 (+1.03%)
BAC   23.91 (-2.84%)
BA   180.60 (-3.91%)
QQQ   258.82 (-0.80%)
AAPL   385.03 (-1.50%)
MSFT   204.02 (-1.93%)
FB   240.37 (+0.04%)
GOOGL   1,506.39 (-0.69%)
AMZN   3,007.87 (-0.03%)
NVDA   405.55 (-0.87%)
CGC   18.42 (+1.49%)
BABA   244.00 (-2.09%)
MU   50.00 (-1.01%)
GE   7.10 (-0.56%)
TSLA   1,507.14 (-2.51%)
AMD   54.53 (-1.48%)
T   30.22 (+0.70%)
ACB   12.28 (-4.58%)
F   6.86 (+1.78%)
GILD   76.28 (-0.48%)
DIS   119.74 (-0.98%)
NFLX   528.65 (+1.03%)
BAC   23.91 (-2.84%)
BA   180.60 (-3.91%)
Log in

Heron Therapeutics (NASDAQ:HRTX) Given New $19.00 Price Target at SVB Leerink

Last updated on Tuesday, June 30, 2020 | 2020 MarketBeat

Heron Therapeutics (NASDAQ:HRTX) had its target price reduced by analysts at SVB Leerink from $26.00 to $19.00 in a report released on Tuesday, The Fly reports. The brokerage currently has an "outperform" rating on the biotechnology company's stock. SVB Leerink's price target indicates a potential upside of 31.31% from the company's previous close.

A number of other equities analysts have also weighed in on HRTX. FIX initiated coverage on shares of Heron Therapeutics in a research report on Monday, May 18th. They issued an "add" rating for the company. Zacks Investment Research lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating and set a $18.00 price target for the company. in a research report on Wednesday, May 20th. Stifel Nicolaus initiated coverage on shares of Heron Therapeutics in a research report on Monday. They issued a "buy" rating and a $21.00 price target for the company. Needham & Company LLC reiterated a "buy" rating and issued a $44.00 price target on shares of Heron Therapeutics in a research report on Wednesday, April 15th. Finally, Guggenheim began coverage on shares of Heron Therapeutics in a report on Tuesday, May 26th. They issued a "buy" rating and a $24.00 target price on the stock. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Heron Therapeutics has a consensus rating of "Buy" and a consensus target price of $36.10.

Shares of HRTX traded up $0.21 during mid-day trading on Tuesday, reaching $14.47. The stock had a trading volume of 40,375 shares, compared to its average volume of 1,293,829. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -6.37 and a beta of 1.55. Heron Therapeutics has a 12 month low of $9.60 and a 12 month high of $26.81. The business has a fifty day moving average of $18.34 and a 200 day moving average of $18.55. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.17 and a current ratio of 4.53.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.08. The business had revenue of $25.40 million during the quarter, compared to analyst estimates of $21.23 million. Heron Therapeutics had a negative net margin of 138.31% and a negative return on equity of 56.85%. The company's revenue was down 19.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.80) earnings per share. On average, research analysts forecast that Heron Therapeutics will post -2.33 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Sowell Financial Services LLC raised its position in Heron Therapeutics by 2,443.5% during the 1st quarter. Sowell Financial Services LLC now owns 2,340 shares of the biotechnology company's stock worth $27,000 after buying an additional 2,248 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Heron Therapeutics by 259.7% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,579 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 1,862 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Heron Therapeutics by 325.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,698 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 2,064 shares during the period. Quantbot Technologies LP grew its stake in shares of Heron Therapeutics by 433.3% during the 4th quarter. Quantbot Technologies LP now owns 5,333 shares of the biotechnology company's stock worth $125,000 after purchasing an additional 4,333 shares during the period. Finally, Great West Life Assurance Co. Can grew its stake in shares of Heron Therapeutics by 19.9% during the 4th quarter. Great West Life Assurance Co. Can now owns 6,097 shares of the biotechnology company's stock worth $142,000 after purchasing an additional 1,010 shares during the period.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: What is a Lock-Up Period?

The Fly

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

8 Stocks You Can Count On During Any Crisis

Depending on how you look at it, the economic outlook is getting cloudier or clearer.

The argument for a cloudy economy is easy to make. Multiple times of day we hear about more Americans testing positive for the novel coronavirus. The worldwide number of positive tests exceeds one million. And unfortunately, it will go higher. We just don’t know by how much.

But there are two parts to this ongoing situation. The first is the real-time science experiment as the world attempts to flatten the curve. The other is the very real economic impact. And the numbers of the economic carnage are coming in faster than any significant evidence of a flattening curve.

The number of unemployed now exceeds six million and will only rise. The government is throwing everything including the kitchen sink at the problem. But it’s an experiment in real-time. We won’t know the results for some time.

But even while we wait for a new normal to return, there are ways for you to profit. There are companies that are keeping our economy going now, and have a business model that sets them up well for success after the pandemic is over.

View the "8 Stocks You Can Count On During Any Crisis".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.